1. Scrip
  2. >>Business
  3. >>Deals

Private Equity Firm EQT Hopes Higher Cash Offer Will Win It Karo Pharma

 
• By Sten Stovall

Private equity firm EQT hopes a higher cash offer for Swedish specialty pharma group Karo Pharma than the one it made two months ago will persuade reluctant shareholders in the biotech to now sell their holdings.

Money
EQT raised its cash offer for Swedish specialty pharma group Karo Pharma • Source: Shutterstock

In an effort to win over hesitant investors, Sweden-based private equity group EQT raised its cash offer for Swedish specialty pharma group Karo Pharma AB to SEK6.15bn ($684m), saying the move was in part in response to stock market declines since its original offer was tabled in late October.

Stockholm-listed Karo Pharma focuses on researching and developing novel medicines based on the nuclear receptors, and collaborates with, among others,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.